BI-2 destabilizes HIV-1 cores during infection and Prevents Binding of CPSF6 to the HIV-1 Capsid

Retrovirology

Felipe Diaz-Griffero¹  Jose Valle-Casuso²  Silvana Opp²  Cindy Buffone²  Thomas Fricke² 

[1] Albert Einstein College of Medicine, 1301 Morris Park – Price Center 501, New York 10461, NY, USA;Department of Microbiology and Immunology, Albert Einstein College of Medicine Bronx, Bronx 10461, NY, USA

关键词: CPSF6;    Uncoating;    Stability;    Capsid;    PF74;    BI-2;    HIV-1;   

Others  :  1151500
DOI  :  10.1186/s12977-014-0120-x

 received in 2014-05-07, accepted in 2014-12-02,  发布年份 2014

【 摘 要 】

Background

The recently discovered small-molecule BI-2 potently blocks HIV-1 infection. BI-2 binds to the N-terminal domain of HIV-1 capsid. BI-2 utilizes the same capsid pocket used by the small molecule PF74. Although both drugs bind to the same pocket, it has been proposed that BI-2 uses a different mechanism to block HIV-1 infection when compared to PF74.

Findings

This work demonstrates that BI-2 destabilizes the HIV-1 core during infection, and prevents the binding of the cellular factor CPSF6 to the HIV-1 core.

Conclusions

Overall this short-form paper suggests that BI-2 is using a similar mechanism to the one used by PF74 to block HIV-1 infection.

【 授权许可】

   
2014 Fricke et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Lamorte L, Titolo S, Lemke CT, Goudreau N, Mercier JF, Wardrop E, Shah VB, von Schwedler UK, Langelier C, Banik SSR, Aiken C, Sundquist WI, Mason SW: Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes. Antimicrob Agents Chemother 2013, 57:4622-4631.
• [2]Fricke T, Brandariz-Nunez A, Wang X, Smith AB, Diaz-Griffero F: Human cytosolic extracts stabilize the HIV-1 core. J Virol 2013, 87:10587-10597.
• [3]Sundquist WI, Hill CP: How to assemble a capsid. Cell 2007, 131:17-19.
• [4]Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, Bazin R, Cao J, Ciaramella G, Isaacson J, Jackson L, Hunt R, Kjerrstrom A, Nieman JA, Patick AK, Perros M, Scott AD, Whitby K, Wu H, Butler SL: HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog 2010, 6:e1001220.
• [5]Shi J, Zhou J, Shah VB, Aiken C, Whitby K: Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J Virol 2010, 85:542-549.
• [6]Price AJ, Fletcher AJ, Schaller T, Elliott T, Lee K, KewalRamani VN, Chin JW, Towers GJ, James LC: CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS Pathog 2012, 8:e1002896.
• [7]Sasaki DT, Dumas SE, Engleman EG: Discrimination of viable and non-viable cells using propidium iodide in two color immunofluorescence. Cytometry 1987, 8:413-420.
• [8]Spence RA, Kati WM, Anderson KS, Johnson KA: Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995, 267:988-993.
• [9]Roa A, Hayashi F, Yang Y, Lienlaf M, Zhou J, Shi J, Watanabe S, Kigawa T, Yokoyama S, Aiken C, Diaz-Griffero F: RING domain mutations uncouple TRIM5 restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating. J Virol 2012, 86:1717-1727.
• [10]Yang Y, Fricke T, Diaz-Griffero F: Inhibition of reverse transcriptase activity increases stability of the HIV-1 core. J Virol 2012, 87:683-687.
• [11]Yang Y, Luban J, Diaz-Griffero F: The fate of HIV-1 capsid: a biochemical assay for HIV-1 uncoating. Methods Mol Biol 2014, 1087:29-36.
• [12]Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, Diaz-Griffero F, Anderson DJ, Sundquist WI, Sodroski J: Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A 2006, 103:5514-5519.
• [13]Diaz-Griffero F, Kar A, Lee M, Stremlau M, Poeschla E, Sodroski J: Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp. Virology 2007, 369:400-410.
• [14]Ganser BK, Li S, Klishko VY, Finch JT, Sundquist WI: Assembly and analysis of conical models for the HIV-1 core. Science 1999, 283:80-83.
• [15]Briggs JAG, Kräusslich H-G: The molecular architecture of HIV. J Mol Biol 2011, 410:491-500.
• [16]Ganser-Pornillos BK, Yeager M, Sundquist WI: The structural biology of HIV assembly. Curr Opin Struct Biol 2008, 18:203-217.
• [17]Fricke T, Valle-Casuso JC, White TE, Brandariz-Nuñez A, Bosche WJ, Reszka N, Gorelick R, Diaz-Griffero F: The ability of TNPO3-depleted cells to inhibit HIV-1 infection requires CPSF6. Retrovirology 2013, 10:46. BioMed Central Full Text
• [18]Lee K, Ambrose Z, Martin TD, Oztop I, Mulky A, Julias JG, Vandegraaff N, Baumann JG, Wang R, Yuen W, Takemura T, Shelton K, Taniuchi I, Li Y, Sodroski J, Littman DR, Coffin JM, Hughes SH, Unutmaz D, Engelman A, KewalRamani VN: Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe 2010, 7:221-233.
• [19]De Iaco A, Santoni F, Vannier A, Guipponi M, Antonarakis S, Luban J: TNPO3 protects HIV-1 replication from CPSF6-mediated capsid stabilization in the host cell cytoplasm. Retrovirology 2013, 10:20. BioMed Central Full Text
• [20]Song B, Javanbakht H, Perron M, Park DH, Stremlau M, Sodroski J: Retrovirus restriction by TRIM5alpha variants from old world and new world primates. J Virol 2005, 79:3930-3937.
• [21]Yang Y, Brandariz-Nuñez A, Fricke T, Ivanov DN, Sarnak Z, Diaz-Griffero F: Binding of the rhesus TRIM5α PRYSPRY domain to capsid is necessary but not sufficient for HIV-1 restriction. Virology 2014, 448:217-228.
• [22]Lienlaf M, Hayashi F, Di Nunzio F, Tochio N, Kigawa T, Yokoyama S, Diaz-Griffero F: Contribution of E3-ubiquitin ligase activity to HIV-1 restriction by TRIM5 rh: structure of the RING domain of TRIM5. J Virol 2011, 85:8725-8737.
• [23]Diaz-Griffero F, Perron M, McGee-Estrada K, Hanna R, Maillard PV, Trono D, Sodroski J: A human TRIM5α B30.2/SPRY domain mutant gains the ability to restrict and prematurely uncoat B-tropic murine leukemia virus. Virology 2008, 378:233-242.
• [24]Matreyek KA, Yücel SS, Li X, Engelman A: Nucleoporin NUP153 phenylalanine-glycine motifs engage a common binding pocket within the HIV-1 capsid protein to mediate lentiviral infectivity. PLoS Pathog 2013, 9:e1003693.